{"a":[{"_":"Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global test","$":{"href":"/pharma/biokin-bispecific-adc-iza-bren-hits-goal-lung-cancer-trial-boosting-case-bms-global-test","hreflang":"en"}}]}
Phase 3positiveiza-brenPositive
AI Analysis
Summary
Biokin Pharma's iza-bren, a first-in-class bispecific antibody-drug conjugate partnered with Bristol Myers Squibb, achieved its primary endpoint in a phase 3 lung cancer trial, strengthening the case for BMS' global development program.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial hit primary goal in lung cancer
Importance:8/10
Sentiment:
0.75
ADCbispecificfirst-in-classlung cancerpartnership
Related Companies
Read the original article
Published by FiercePharma on August 18, 2026 11:06 AM